NCT06728410 2026-03-09
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
Phase 2 Recruiting
Clinical Trials
46 trialsNCT06859684 2026-03-09
HAIC-quad
West China Hospital
Phase 2 Recruiting
NCT07282912 2026-03-04
OLIGOMETS
Yale University
Phase 2 Recruiting
NCT05286814 2026-02-24
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07260175 2026-02-23
adIVO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07146646 2026-02-19
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT07223307 2026-02-09
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
Phase 2 Recruiting
NCT07201519 2026-02-04
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
University of Kentucky
Phase 2 Recruiting
NCT06313203 2026-02-02
TOMCAT
Oslo University Hospital
Phase 2 Recruiting
NCT06048133 2026-01-23
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT05727176 2025-12-29
FOENIX-CCA4
Taiho Oncology, Inc.
Phase 2 Recruiting
NCT06440993 2025-12-01
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06925516 2025-11-28
ACADEMY
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT04891289 2025-11-24
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06529718 2025-11-17
SEVILLA
UNICANCER
Phase 2 Recruiting
NCT06503146 2025-11-12
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05967182 2025-10-24
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06178445 2025-08-19
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07070700 2025-08-12
CASTLE-ZS-02
Fudan University
Phase 2 Recruiting
NCT07105852 2025-08-06
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
Sir Run Run Shaw Hospital
Phase 2 Recruiting
NCT06441747 2025-07-29
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT07063888 2025-07-14
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05422690 2025-07-10
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Inova Health Care Services
Phase 2 Recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06199895 2025-06-03
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Tongji Hospital
Phase 2 Recruiting
NCT06438822 2025-05-07
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
West China Hospital
Phase 2 Recruiting
NCT06888063 2025-03-21
PUMP IV
Erasmus Medical Center
Phase 2 Recruiting
NCT05655949 2025-03-10
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06208462 2025-03-03
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04299581 2025-02-27
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2 Recruiting
NCT04954781 2025-02-27
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2 Recruiting
NCT05010681 2025-02-27
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
Phase 2 Recruiting
NCT05557578 2025-02-11
GOT
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT05532059 2025-02-10
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06607276 2025-01-16
ACHIEVE
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06664021 2025-01-10
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital
Phase 2 Recruiting
NCT06721286 2024-12-06
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06341764 2024-11-07
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06192797 2024-11-05
CCGLC-013
Tongji Hospital
Phase 2 Recruiting
NCT03991832 2024-07-18
SOLID
University Health Network, Toronto
Phase 2 Recruiting
NCT06298968 2024-07-03
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT04834674 2024-06-25
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Recruiting
NCT06375915 2024-05-24
PM-CARE
IRCCS San Raffaele
Phase 2 Recruiting
NCT06296563 2024-04-17
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06335927 2024-03-28
HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC
Fudan University
Phase 2 Recruiting